- Home
- MGNX vs CIA Comparison
MGNX vs CIA Comparison
Compare MGNX & CIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- CIA
- Stock Information
- Founded
- MGNX 2000
- CIA 1969
- Country
- MGNX United States
- CIA United States
- Employees
- MGNX N/A
- CIA N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- CIA Life Insurance
- Sector
- MGNX Health Care
- CIA Finance
- Exchange
- MGNX Nasdaq
- CIA Nasdaq
- Market Cap
- MGNX 202.7M
- CIA 230.6M
- IPO Year
- MGNX 2013
- CIA N/A
- Fundamental
- Price
- MGNX $2.86
- CIA $5.07
- Analyst Decision
- MGNX Hold
- CIA
- Analyst Count
- MGNX 10
- CIA 0
- Target Price
- MGNX $7.17
- CIA N/A
- AVG Volume (30 Days)
- MGNX 642.4K
- CIA 101.9K
- Earning Date
- MGNX 03-06-2025
- CIA 03-13-2025
- Dividend Yield
- MGNX N/A
- CIA N/A
- EPS Growth
- MGNX N/A
- CIA N/A
- EPS
- MGNX N/A
- CIA 0.43
- Revenue
- MGNX $141,329,000.00
- CIA $248,376,000.00
- Revenue This Year
- MGNX $174.73
- CIA N/A
- Revenue Next Year
- MGNX N/A
- CIA $3.85
- P/E Ratio
- MGNX N/A
- CIA $11.17
- Revenue Growth
- MGNX 16.68
- CIA 3.02
- 52 Week Low
- MGNX $2.79
- CIA $1.78
- 52 Week High
- MGNX $21.88
- CIA $5.95
- Technical
- Relative Strength Index (RSI)
- MGNX 34.55
- CIA 60.35
- Support Level
- MGNX $2.93
- CIA $4.69
- Resistance Level
- MGNX $3.16
- CIA $4.95
- Average True Range (ATR)
- MGNX 0.18
- CIA 0.26
- MACD
- MGNX -0.02
- CIA 0.04
- Stochastic Oscillator
- MGNX 1.90
- CIA 67.86
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About CIA Citizens Inc. ($1.00 Par)
Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. the Company derives its revenues principally from life insurance premiums earned for insurance coverages provided to insureds in our two operating segments and net investment income. The company operates in two business segments namely the Life Insurance segment and the Home Service Insurance segment. The company majority generates revenues from Life Insurance segment.